Compare KEQU & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | CING |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.9M | 93.1M |
| IPO Year | 1995 | N/A |
| Metric | KEQU | CING |
|---|---|---|
| Price | $34.43 | $5.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 4.1K | ★ 542.3K |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.64 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $30.33 | $3.20 |
| 52 Week High | $60.89 | $11.89 |
| Indicator | KEQU | CING |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 37.37 |
| Support Level | $33.70 | $3.62 |
| Resistance Level | $41.26 | $6.85 |
| Average True Range (ATR) | 0.66 | 0.52 |
| MACD | 0.31 | -0.14 |
| Stochastic Oscillator | 93.66 | 8.15 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.